CDK-002 is under clinical development by Codiak BioSciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CDK-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CDK-002 is under development for the treatment of solid tumors including triple-negative breast cancer and head and neck squamous cell carcinoma, HCC, cutaneous squamous cell carcinoma, anaplastic thyroid cancer, glioblastoma multiforme (GBM), cervical cancer, sarcomas, muscle invasive bladder cancer (MIBC) and leptomeningeal disease (LMD). The therapeutic candidates comprise of genetically altered exosomes overexpressing PTGFRN and loaded with a cyclic dinucleotide (CDN) small molecule STING agonist which gets delivered to antigen presenting cells (APC). They are developed based on engEx platform. It is administered through intratumor and intrathecal route. It was also under development for the treatment of lung cancer and infectious diseases.
Codiak BioSciences overview
Codiak BioSciences is an exosome therapeutics company. The company focuses on the development of proprietary pipeline of targeted medicines for diseases with unmet medical needs. Its engEx platform capitalizes on exosomes, which are nanometer-sized membrane sacs that delivers proteins, lipids, nucleic acids, and small molecules to various cell types. Codiak BioSciences latest pipeline products includes exoSTING, exoIL-12, exoASO-STAT6, oncogene targets, exoASO-NLRP3, gene targets, exoVACC and exoASO-NRAS. The company also has rights to a novel investigational drug candidate for the treatment of pancreatic cancer, from The University of Texas, MD Anderson Cancer Center. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CDK-002’s drug-specific PTSR and LoA scores, buy the report here.